These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36822869)

  • 21. Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States.
    Zhao JZ; Weinhandl ED; Carlson AM; St Peter WL
    Kidney Med; 2023 Jan; 5(1):100564. PubMed ID: 36593878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life.
    Longato E; Di Camillo B; Sparacino G; Gubian L; Avogaro A; Fadini GP
    BMJ Open Diabetes Res Care; 2020 Jun; 8(1):. PubMed ID: 32591373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardio-renal outcomes and the direct medical cost of type 2 diabetes patients treated with sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based cohort study.
    Tang EHM; Wong CKH; Lau KTK; Fei Y; Cheung BMY
    Diabetes Res Clin Pract; 2021 Oct; 180():109071. PubMed ID: 34592391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The comparative effects of metabolic surgery, SGLT2i, or GLP-1RA in patients with obesity and type 2 diabetes: a retrospective cohort study.
    Wu T; Wong CKH; Tang EHM; Man KKC; Wong SKH; Au ICH; Tse ETY; Chan EWY; Grieve E; Wu O; Ng EKW; Wong ICK
    Surg Obes Relat Dis; 2022 Jun; 18(6):762-771. PubMed ID: 35300912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of glucagon-like peptide-1 receptor agonists for pediatric patients with obesity and diabetes: The providers' perspectives.
    Gourgari E; Huerta-Saenz L; Tonyushkina KN; Rosolowsky ET; Guttmann-Bauman I
    Pediatr Diabetes; 2021 Sep; 22(6):872-875. PubMed ID: 34018306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes.
    O'Keefe JH; Nassif ME; Magwire ML; O'Keefe EL; Lavie CJ
    Prog Cardiovasc Dis; 2019; 62(4):364-369. PubMed ID: 31408637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. County-level variation in cardioprotective antihyperglycemic prescribing among medicare beneficiaries.
    Hanna J; Nargesi AA; Essien UR; Sangha V; Lin Z; Krumholz HM; Khera R
    Am J Prev Cardiol; 2022 Sep; 11():100370. PubMed ID: 35968531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study.
    DeRemer CE; Vouri SM; Guo J; Donahoo WT; Winterstein AG; Shao H
    J Diabetes Complications; 2021 Sep; 35(9):107972. PubMed ID: 34247911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
    Fadini GP; Sciannameo V; Franzetti I; Bottigliengo D; D'Angelo P; Vinci C; Berchialla P; Arena S; Buzzetti R; Avogaro A;
    Diabetes Obes Metab; 2019 Aug; 21(8):1886-1894. PubMed ID: 30985052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis.
    Ali MU; Mancini GBJ; Fitzpatrick-Lewis D; Lewis R; Jovkovic M; Zieroth S; O'Meara E; Connelly KA; Sherifali D
    Can J Cardiol; 2022 Aug; 38(8):1201-1210. PubMed ID: 35961756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy.
    Fadini GP; Frison V; Rigato M; Morieri ML; Simioni N; Tadiotto F; D'Ambrosio M; Paccagnella A; Lapolla A; Avogaro A
    Acta Diabetol; 2020 Mar; 57(3):367-375. PubMed ID: 31673896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study.
    Harris ST; Patorno E; Zhuo M; Kim SC; Paik JM
    Diabetes Care; 2021 Aug; 44(10):2293-301. PubMed ID: 34344714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.
    Korayem GB; Alshaya OA; Alghamdi AA; Alanazi SS; Almutib RT; Alsaileek M; Alrashidi A; Aldosari N; Bin Sheraim N; Al Yami MS; Almohammed OA
    Front Public Health; 2022; 10():1031306. PubMed ID: 36408008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA.
    Khat DZ; Husain M
    Curr Diab Rep; 2018 Jun; 18(7):45. PubMed ID: 29886514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low Use of Guideline-recommended Cardiorenal Protective Antihyperglycemic Agents in Primary Care: A Cross-sectional Study of Adults With Type 2 Diabetes.
    Marasinghe DH; Butalia S; Garies S; Drummond N; Kim JW; Senior PA
    Can J Diabetes; 2022 Jul; 46(5):487-494. PubMed ID: 35739042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients.
    Pablo A; Evelyn B; Claudia F; Yanina MA
    Curr Hypertens Rev; 2021; 17(2):149-158. PubMed ID: 33238857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program.
    Salahuddin T; Richardson V; McNeal DM; Henderson K; Hess PL; Raghavan S; Saxon DR; Valle JA; Waldo SW; Ho PM; Schwartz GG
    Diabetes Obes Metab; 2021 Jan; 23(1):97-105. PubMed ID: 32902128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CVOTs: What did the endocrinologist learn?
    Valensi P; Prévost G
    Diabetes Res Clin Pract; 2020 Jan; 159():107947. PubMed ID: 31778747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.